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INTRODUCTION
Simultaneous imaging with magnetic resonance
imaging (MRI) and positron emission tomography
(PET) is valuable in various cardiac diseases.1,2 Altered
myocardial metabolism has been reported in hyper-
trophic cardiomyopathy (HCM).3 In this study, we
report an instructive case of HCM with intense 18F-
fluorodeoxyglucose (FDG) uptake in the hypertrophied
myocardium detected by PET/MRI.
CASE SUMMARY
A 57-year-old female was referred to our hospital
for severe left ventricular hypertrophy (LVH). Although
she had no symptoms and no history of hypertension,
echocardiography demonstrated severe LVH in the mid
LV to the apex with no asymmetric septal hypertrophy.
Thus, we suspected apical type of HCM and performed
FDG-PET/MRI. After fasting for more than 18 hours,
the patient was administered unfractionated heparin 50
IU/kg intravenously 15 minutes before FDG adminis-
tration to suppress physiological FDG uptake on the
myocardium.2 Image acquisition was initiated 60 min
after FDG administration. Cine MRI images (Videos 1
and 2 in supplementary material) showed severe hyper-
trophy in the middle region of the LV with no LV
outflow obstruction. However, myocardial thinning and
reduced wall motion were observed in the apex. Intense
FDG uptake was observed in the LV, suggesting a
metabolic substrate switching from fatty acids to glu-
cose, and FDG uptake was relatively low, and late
gadolinium enhancement was evident in the apex
(Figures 1, 2). Fusion images clearly showed FDG
uptake on the hypertrophied myocardium. It should be
noted that, although we used prolonged fasting and
intravenous heparin, distinguishing physiological uptake
of FDG from pathological uptake related to metabolic
switching might be sometimes challenging. Simultane-
ous PET/MRI was able to reconstruct accurate fusion
images and provided anatomic and metabolic character-
izations of the hypertrophied heart. Myocardial biopsy
revealed cardiomyocyte hypertrophy with mere disarray,
slight fibrosis, and no inflammatory cell infiltration,
consistent with pathological findings of HCM. There
were no signs suggestive of secondary cardiomyopathy,
which represents cardiac hypertrophy. The PET/MRI is
Figure 1. 18F-fluorodeoxyglucose PET/MRI images of 2- and
4-chamber views. Intense 18F-fluorodeoxyglucose (FDG)
uptake was observed on the middle walls in the left ventricular
myocardium. Late gadolinium enhancement (LGE) was
detected on the apex. Fusion images clearly showed the
markedly increased FDG uptake in hypertrophied myocardial
regions.
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a novel useful imaging technology to evaluate structural
and functional abnormalities in HCM.
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Figure 2. Serial short-axis images of 18F-fluorodeoxyglucose
PET/MRI. 18F-fluorodeoxyglucose (FDG), late gadolinium
enhancement (LGE), and fusion images from base (upper) to
apex (lower).
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